专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5206223A Method for inhibiting heparanase activity 失效
标题翻译：抑制肝素酶活性的方法
公开(公告)号：US5206223A
公开(公告)日：1993-04-27
申请号：US583851
申请日：1990-09-17
申请人： Israel Vlodavsky , Amiram Eldor , Yaakov Naparstek , Irun Cohen
发明人： Israel Vlodavsky , Amiram Eldor , Yaakov Naparstek , Irun Cohen
IPC分类号： C08B37/10
CPC分类号： A61K31/715 , Y10S514/825 , Y10S514/885
摘要： Heparanase activity in a patient may be inhibited by administering an effective heparanase-inhibiting amount of heparin or an effective chemically modified derivative of heparin which inhibits heparanase activity. Such derivatives are preferably N-desulfated, N-acetylated heparin or O-desulfated, N-acetylated heparin. By means of this invention, allograft rejection may be prevented or delayed and autoimmune diseases such as arthritis may be alleviated and treated.
摘要翻译：可以通过施用抑制肝素酶活性的有效的乙酰肝素酶抑制量的肝素或有效的化学修饰的肝素衍生物来抑制患者中的肝素酶活性。此类衍生物优选为N-脱硫酸，N-乙酰化肝素或O-脱硫酸，N-乙酰化肝素。通过本发明，可以预防或延迟同种异体移植排斥反应，并且可以减轻和治疗自身免疫性疾病如关节炎。

2. 发明授权

US4882318A Method for decreasing tumor metastasis 失效
标题翻译：减少肿瘤转移的方法
公开(公告)号：US4882318A
公开(公告)日：1989-11-21
申请号：US67582
申请日：1987-06-24
申请人： Israel Vlodavsky , Amiram Eldor , Yaakov Naparstek , Irun R. Cohen
发明人： Israel Vlodavsky , Amiram Eldor , Yaakov Naparstek , Irun R. Cohen
IPC分类号： A61K31/715 , A61K20060101 , A61P35/00 , A61P43/00 , C08B37/10
CPC分类号： A61K31/715
摘要： The invention relates to pharmaceutical compositions intended to decrease the incidence of tumor metastasis in patients who suffer from malignant diseases.The pharmaceutical compositions of the invention contain as active ingredient heparin or a suitable derivative thereof. Amongst suitable derivatives are N-desulfated and N-acetylated heparin.The dosage of the administered heparin or heparin derivative is quite critical and will generally be in the range of from 0.05 mg/kg/day to about 0.5 mg/kg/day. A preferred range is between about 0.1 mg/kg/day to about 0.5 mg/kg/day.
摘要翻译：本发明涉及旨在降低患有恶性疾病的患者的肿瘤转移发生率的药物组合物。本发明的药物组合物含有作为活性成分的肝素或其合适的衍生物。其中合适的衍生物是N-脱硫和N-乙酰化肝素。给药的肝素或肝素衍生物的剂量是非常关键的，通常在0.05mg / kg /天至约0.5mg / kg /天的范围内。优选的范围为约0.1mg / kg /天至约0.5mg / kg /天。

3. 发明授权

US08420092B2 Method of treating diabetes by administering an anti-NKp46 antibody 有权
标题翻译：通过施用抗NKp46抗体治疗糖尿病的方法
公开(公告)号：US08420092B2
公开(公告)日：2013-04-16
申请号：US13257349
申请日：2010-03-18
申请人： Ofer Mandelboim , Angel Porgador , Yaakov Naparstek , Chamutal Gur
发明人： Ofer Mandelboim , Angel Porgador , Yaakov Naparstek , Chamutal Gur
IPC分类号： A61K38/177 , C07K14/705 , C07K14/70503 , C07K16/2803 , A61K2039/505
CPC分类号： A61K39/3955 , A61K38/00 , A61K2039/505 , C07K14/705 , C07K14/70503 , C07K16/2803 , C07K16/2851 , C07K2319/30
摘要： The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.
摘要翻译：本发明涉及天然细胞毒性受体NKp46用于预防和治疗糖尿病，包括I型糖尿病（TID）和2型糖尿病的用途。特别地，本发明提供了包含NKp46细胞外区域片段的组合物，用于预防糖尿病的发病和进展。

4. 发明申请

US20090181028A1 B-CELL EPITOPE PEPTIDES OF HSP 65, NOVEL AMINO ACID SEQUENCES, DNA ENCODING THE AMINO ACID SEQUENCES OF SAID PEPTIDES, ANTIBODIES DIRECTED AGAINST SAID PEPTIDES AND DIFFERENT USES THEREOF IN THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES 有权
标题翻译： HSP65的B细胞抗原肽肽，新型氨基酸序列，编码抗原肽的氨基酸序列的DNA，针对抗原肽的抗体及其在治疗炎症和自身免疫性疾病中的不同用途
公开(公告)号：US20090181028A1
公开(公告)日：2009-07-16
申请号：US12344919
申请日：2008-12-29
申请人： Yaakov Naparstek , Rina Ulmansky , Yechezkei Kashi
发明人： Yaakov Naparstek , Rina Ulmansky , Yechezkei Kashi
IPC分类号： A61K39/395 , C07K14/00 , A61K38/00
CPC分类号： C07K14/35 , A61K39/00 , A61K2039/505 , C07K14/47 , C07K16/1289 , C07K16/18
摘要： B-cell epitope peptides of HSP 65, particularly the peptides comprising the amino acid sequence substantially as denoted by SEQ ID: NOs. 1-5 and their biologically functional homologues and derivatives thereof. Also included are polyclonal and monoclonal antibodies directed against them and their compositions for passive immunization against inflammatory and autoimmune diseases and in the treatment of inflammatory and autoimmune diseases. Also encompassed are diagnostic uses of these antibodies, for identifying people at risk of developing arthritis or diabetes, and a method of monitoring progress of the disease conditions and disease prognosis.
摘要翻译： HSP65的B细胞表位肽，特别是包含基本上如SEQ ID NO：所示的氨基酸序列的肽。 1-5及其生物功能同系物及其衍生物。还包括针对它们的多克隆和单克隆抗体及其针对炎症和自身免疫疾病的被动免疫以及治疗炎性和自身免疫性疾病的组合物。还包括这些抗体的诊断用途，用于鉴定发生关节炎或糖尿病风险的人，以及监测疾病状况和疾病预后进展的方法。

5. 发明授权

US06228363B1 Peptides for the treatment of systemic lupus erythematosus 失效
标题翻译：用于治疗系统性红斑狼疮的肽
公开(公告)号：US06228363B1
公开(公告)日：2001-05-08
申请号：US09399494
申请日：1999-09-20
申请人： Yaakov Naparstek
发明人： Yaakov Naparstek
IPC分类号： A61K3900
CPC分类号： C07K14/78 , A61K38/00
摘要： A method is disclosed for treating systemic lupus erythematosus in a mammalian subject, comprising administering to said subject an effective dose of at least one laminin peptide, or an analog or a derivative thereof. In one exemplary embodiment, the laminin peptide is selected from the group consisting of R38, and claimed R38 analogs and derivatives thereof including 5200, 5104, 5105, 5106, 5107, 5108, 5109, and 5110. The laminin peptides of the present invention may be prepared by known chemical synthetic methods or by biotechnological methods. Assays useful for the diagnosis of and following pathological activity course of systemic lupus erythematosus in patients suffering therefrom.
摘要翻译：公开了用于治疗哺乳动物受试者的系统性红斑狼疮的方法，包括向所述受试者施用有效剂量的至少一种层粘连蛋白肽或其类似物或衍生物。在一个示例性实施方案中，层粘连蛋白肽选自R38和所要求的R38类似物及其衍生物，包括5200,5104,4105,5106,5107,510,510,5110和5110.本发明的层粘连蛋白肽可以通过已知的化学合成方法或通过生物技术方法制备。用于诊断患病的患者的系统性红斑狼疮病理学活动过程的诊断和检测。

6. 发明授权

US08680241B2 Humanized antibodies specific for HSP65-derived peptide-6 methods and uses thereof 有权
标题翻译：对HSP65衍生的肽-6方法有特异性的人源化抗体及其用途
公开(公告)号：US08680241B2
公开(公告)日：2014-03-25
申请号：US13392548
申请日：2010-09-06
申请人： Yaakov Naparstek , Shira Yair
发明人： Yaakov Naparstek , Shira Yair
IPC分类号： C07K16/00 , C12P21/08 , A61K39/395 , A61K39/00 , C07H21/04
CPC分类号： C07K16/1289 , A61K2039/505 , C07K16/18 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/75 , C07K2317/92
摘要： The present invention relates to humanized antibodies that specifically bind a polypeptide comprising peptide-6 as denoted by SEQ ID NO. 15, that is an HSP65 derived peptide. More specifically, the invention relates to humanized anti-peptide-6 antibodies, compositions, methods and uses thereof for the treatment of immune-related disorders, specifically, inflammatory disorders such as arthritis, IBD, psoriasis, diabetes and MS. The invention further provides combined compositions and kit combining the humanized antibodies of the invention and at least one anti-inflammatory agent, as well as uses of the humanized antibodies in diagnostic kits and methods.
摘要翻译：本发明涉及特异性结合包含肽-6的多肽的人源化抗体，如SEQ ID NO： 15，即HSP65衍生肽。更具体地说，本发明涉及用于治疗免疫相关疾病，特别是诸如关节炎，IBD，牛皮癣，糖尿病和MS的炎性疾病的人源化抗肽-6抗体，组合物，方法和用途。本发明进一步提供将本发明的人源化抗体与至少一种抗炎剂组合的组合组合物和试剂盒，以及人源化抗体在诊断试剂盒和方法中的用途。

7. 发明授权

US07744920B2 Use of liposomal glucocorticoids for treating inflammatory states 有权
标题翻译：使用脂质体糖皮质激素治疗炎症状态
公开(公告)号：US07744920B2
公开(公告)日：2010-06-29
申请号：US11662174
申请日：2005-09-11
申请人： Yechezkel Barenholz , Yaakov Naparstek , Yuval Avnir , Rina Ulmansky
发明人： Yechezkel Barenholz , Yaakov Naparstek , Yuval Avnir , Rina Ulmansky
IPC分类号： A61K9/127 , A61K31/56
CPC分类号： A61K9/127 , A61K9/1271 , A61K31/573
摘要： The present invention provides the use of a glucocorticoid (GC) or of a GC derivative encapsulated in a liposome for the preparation of a pharmaceutical composition for the treatment of an inflammatory associated condition in a subject, provided that said condition is not associated with a neurodegenerative disease or disorder. A specific use concerns a liposomal formulation comprising methylprednisolone sodium hemisuccinate (MPS) for the treatment of rheumatoid arthritis.
摘要翻译：本发明提供糖皮质激素（GC）或包封在脂质体中的GC衍生物用于制备用于治疗受试者的炎症相关病症的药物组合物的用途，条件是所述病症与神经变性不相关疾病或病症。具体用途涉及包含用于治疗类风湿性关节炎的甲泼尼龙钠半琥珀酸钠（MPS）的脂质体制剂。

8. 发明授权

US07488476B2 B-cell epitope peptides of HSP 65, DNA encoding said peptides, antibodies directed against said peptides and the different uses thereof in the treatment of inflammatory and autoimmune diseases 失效
标题翻译： HSP65的B细胞表位肽，编码所述肽的DNA，针对所述肽的抗体及其在治疗炎性和自身免疫性疾病中的不同用途
公开(公告)号：US07488476B2
公开(公告)日：2009-02-10
申请号：US10931944
申请日：2004-08-31
申请人： Yaakov Naparstek , Rina Ulmansky , Yechezkel Kashi
发明人： Yaakov Naparstek , Rina Ulmansky , Yechezkel Kashi
IPC分类号： A61K39/395
CPC分类号： C07K14/47 , C07K14/35
摘要： B-cell epitope peptides of HSP 65, particularly the peptides comprising the amino acid sequence substantially as denoted by SEQ ID: Nos. 1-5 and their biologically functional homologues and derivatives thereof. Also included are polyclonal and monoclonal antibodies directed against them and their compositions for passive immunization against inflammatory and autoimmune diseases and in the treatment of inflammatory and autoimmune diseases. Also encompassed are diagnostic uses of these antibodies, for identifying people at risk of developing arthritis or diabetes, and a method of monitoring progress of the disease conditions and disease prognosis.
摘要翻译： HSP65的B细胞表位肽，特别是包含基本上如SEQ ID：1-5所示的氨基酸序列的肽及其生物功能同系物及其衍生物。还包括针对它们的多克隆和单克隆抗体及其针对炎症和自身免疫疾病的被动免疫以及治疗炎性和自身免疫性疾病的组合物。还包括这些抗体的诊断用途，用于鉴定发生关节炎或糖尿病风险的人，以及监测疾病状况和疾病预后进展的方法。

9. 发明申请

US20120156201A1 HUMANIZED ANTIBODIES SPECIFIC FOR HSP65-DERIVED PEPTIDE-6 METHODS AND USES THEREOF 有权
标题翻译： HSP65衍生肽-EP方法及其用途的人体抗体特异性
公开(公告)号：US20120156201A1
公开(公告)日：2012-06-21
申请号：US13392548
申请日：2010-09-06
申请人： Yaakov Naparstek , Shira Yair
发明人： Yaakov Naparstek , Shira Yair
IPC分类号： A61K39/395 , C07K16/00 , A61P37/00 , A61P3/10 , A61P19/02 , A61P1/00 , A61P17/06 , C12N5/16 , A61P29/00
CPC分类号： C07K16/1289 , A61K2039/505 , C07K16/18 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/75 , C07K2317/92
摘要： The present invention relates to humanized antibodies that specifically bind a polypeptide comprising peptide-6 as denoted by SEQ ID NO. 15, that is an HSP65 derived peptide. More specifically, the invention relates to humanized anti-peptide-6 antibodies, compositions, methods and uses thereof for the treatment of immune-related disorders, specifically, inflammatory disorders such as arthritis, IBD, psoriasis, diabetes and MS. The invention further provides combined compositions and kit combining the humanized antibodies of the invention and at least one anti-inflammatory agent, as well as uses of the humanized antibodies in diagnostic kits and methods.
摘要翻译：本发明涉及特异性结合包含肽-6的多肽的人源化抗体，如SEQ ID NO： 15，即HSP65衍生肽。更具体地说，本发明涉及用于治疗免疫相关疾病，特别是诸如关节炎，IBD，牛皮癣，糖尿病和MS的炎性疾病的人源化抗肽-6抗体，组合物，方法和用途。本发明进一步提供将本发明的人源化抗体与至少一种抗炎剂组合的组合组合物和试剂盒，以及人源化抗体在诊断试剂盒和方法中的用途。

10. 发明申请

US20120014973A1 ADENYLYL CYCLASE-ASSOCIATED PROTEIN (CAP1) AND USES THEREOF AS A TARGET FOR IMMUNO-MODULATION 有权
标题翻译：联合循环相关蛋白（CAP1）及其作为免疫调节目标的用途
公开(公告)号：US20120014973A1
公开(公告)日：2012-01-19
申请号：US13257633
申请日：2010-03-21
申请人： Yaakov Naparstek , Eli Moallem
发明人： Yaakov Naparstek , Eli Moallem
IPC分类号： A61K39/395 , C07K14/47 , A61P37/02 , A61K38/17 , A61P29/00 , C07K16/18 , G01N33/566
CPC分类号： C07K16/28 , C07K16/1289 , C07K2317/24 , C07K2317/34 , C07K2317/54 , C07K2317/75 , C12N9/00 , C12N15/113 , C12N2310/14
摘要： The present invention relates to the use of Adenylyl Cyclase-Associated Protein (CAP1) as a target for immuno-modulation. More specifically, the invention relates to the use of compounds that interact and bind CAP1, specifically, anti-CAP1 antibodies, and/or to CAP1 molecule or any fragments thereof, for the treatment of immune-related disorders by modulation of the Th1/Th2 balance. The invention further provides screening method for immuno-modulatory compounds that interact with CAP1.
摘要翻译：本发明涉及腺苷酸环化酶相关蛋白（CAP1）作为免疫调节靶标的用途。更具体地，本发明涉及通过调节Th1 / Th2相互作用并结合CAP1，特别是抗CAP1抗体和/或CAP1分子或其任何片段的化合物用于治疗免疫相关疾病的用途平衡。本发明还提供了与CAP1相互作用的免疫调节化合物的筛选方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式